Inventiva IVA
NASDAQ IVA
$4.78 -0.06 (-1.24%)
As of: Sep 4, 2026 · 3:59 PM EDT

Inventiva (IVA) Long-Term Debt Repayments (2019 - 2025)

Inventiva (IVA) posted quarterly Long-Term Debt Repayments of -$2.0 million for Q2 2025, down 59.95% year-over-year from -$5.1 million in Q2 2024, and down 5.93% quarter-over-quarter from -$1.9 million in Q4 2024.

Analysis

Inventiva (IVA) Long-Term Debt Repayments (2019 - 2025) Analysis & Trends

Inventiva's Long-Term Debt Repayments history runs 6 years deep, the most recent figure standing at -$2.0 million for Q2 2025.

  • In Q2 2025, Long-Term Debt Repayments fell 59.95% year-over-year to -$2.0 million; the TTM figure through Jun 2025 stood at -$3.3 million (down 154.98% YoY), while the FY2024 annual figure was -$1.9 million, up 28.42% from the prior year.
  • Long-Term Debt Repayments for Q2 2025 stood at -$2.0 million, down from -$1.9 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was -$14871.6 in Q4 2021, with the low at -$2.7 million in Q4 2023.
  • The 4-year median for Long-Term Debt Repayments is -$1.6 million (2023), against an average of -$1.4 million.
  • The sharpest annual moves came in 2021 and 2025: Long-Term Debt Repayments surged 74.01% in 2021, then tumbled 59.95% in 2025.
  • Inventiva's Long-Term Debt Repayments stood at -$14871.6 in 2021, then tumbled by 17878.61% to -$2.7 million in 2023, then rose by 28.42% to -$1.9 million in 2024, then dropped by 5.93% to -$2.0 million in 2025.
  • Business Quant data shows IVA's Long-Term Debt Repayments at -$2.0 million in Q2 2025, -$1.9 million in Q4 2024, and -$1.3 million in Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 17.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Inventiva 893.85 Mn 893.85 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -2.03 Mn
Jun 30, 2024 -1.27 Mn
Dec 31, 2021 -14,871.62
Mar 31, 2021 -15,681.07
Dec 31, 2020 -57,229.91
Jun 30, 2020 -15,420.44
Mar 31, 2020 -37,533.93
Dec 31, 2019 -80,802.80